

## Special Issue

# A Mitochondrial Perspective on Noncommunicable Diseases

### Message from the Guest Editor

Noncommunicable diseases (NCDs) are the leading cause of death. Mitochondrial dysfunction has been identified as a major contributing factor in several NCDs, making it pertinent to discuss the mechanisms underlying this and its contribution regarding the initiation and/or progression of NCDs. Understanding the mitochondrial phenotype and treatment responsiveness in NCDs could be a valuable resource concerning its reduction. This Special Issue aims to provide a detailed and updated overview of the mitochondrial contribution to noncommunicable diseases. Please feel free to share your research regarding mitochondrial-targeted strategies concerning diagnosis, metabolism regulation, therapies, and disease prevention contributing to the treatment and reduction in NCDs, also welcoming research and review articles targeting mitochondrial alterations in NCDs. We would also like to encourage articles addressing the contribution of environmental or early-life factors towards the alteration of the mitochondrial biology observed in NCDs.

- noncommunicable diseases
- metabolic disease
- mitochondria
- metabolic sensors
- biomarker
- redox status

### Guest Editor

Dr. Susana P. Pereira

1. Laboratory of Metabolism and Exercise (LaMetEx), Research Center in Physical Activity, health and Leisure (CIAFEL)-Faculty of Sports-University of Porto (FADEUP) and Laboratory for Integrative and Translational Research in Population Health (ITR), 4200-450 Porto, Portugal 2. CNC - Center for Neuroscience and Cell Biology, CIBB - Centre for Innovative Biomedicine and Biotechnology, University of Coimbra, IIIUC - Institute for Interdisciplinary Research, 3004-504 Coimbra, Portugal

### Deadline for manuscript submissions

closed (31 January 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/113770](https://mdpi.com/si/113770)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).